ASCO 2023 | Neoadjuvant biomarker analysis of NeoRHEA: palbociclib in ER+/HER2- BC

Elisa Agostinetto, MD, Institut Jules Bordet, Brussels, Belgium, discusses biomarker findings from the Phase II NeoRHEA trial (NCT03065621) of palbociclib with endocrine therapy in patients with ER+/HER2- breast cancer (BC). 100 patients were enrolled, and identification of biomarkers of no response was the primary endpoint. Cell cycle arrest was observed in a majority of patients, highlighting the efficacy of CDK4/6 inhibitors. High mRNA expression of the CDK6 gene was associated with poor response. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.